These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 38737003)
21. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Wai AK; Chan CY; Cheung AW; Wang K; Chan SC; Lee TT; Luk LY; Yip ET; Ho JW; Tsui OW; Cheung KW; Lee S; Tong CK; Yamamoto T; Rainer TH; Wong EL Lancet Reg Health West Pac; 2023 Jan; 30():100602. PubMed ID: 36212676 [TBL] [Abstract][Full Text] [Related]
22. Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study. Wai AK; Lee TT; Chan SC; Chan CY; Yip ET; Luk LY; Ho JW; So KW; Tsui OW; Lam ML; Lee SY; Yamamoto T; Tong CK; Wong MS; Wong EL; Rainer TH Sci Rep; 2023 May; 13(1):7832. PubMed ID: 37188726 [TBL] [Abstract][Full Text] [Related]
23. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ; Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363 [TBL] [Abstract][Full Text] [Related]
24. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir. Bai F; Beringheli T; Vitaletti V; Santoro A; Molà F; Copes A; Gemignani N; Pettenuzzo S; Castoldi R; Varisco B; Nardo R; Lundgren LB; Ligresti R; Sala M; Albertini L; Augello M; Biasioli L; Bono V; Rovito R; Bini T; Passarella S; Orfeo NV; Monforte AD; Marchetti G Infect Dis Ther; 2024 Jul; 13(7):1589-1605. PubMed ID: 38829439 [TBL] [Abstract][Full Text] [Related]
25. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873 [TBL] [Abstract][Full Text] [Related]
26. Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19). Yip TC; Lui GC; Lai MS; Wong VW; Tse YK; Ma BH; Hui E; Leung MKW; Chan HL; Hui DS; Wong GL Clin Infect Dis; 2023 Feb; 76(3):e26-e33. PubMed ID: 36031408 [TBL] [Abstract][Full Text] [Related]
27. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study. Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN medRxiv; 2022 Dec; ():. PubMed ID: 36561190 [TBL] [Abstract][Full Text] [Related]
29. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation. Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816 [TBL] [Abstract][Full Text] [Related]
30. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study. Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990 [TBL] [Abstract][Full Text] [Related]
31. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309 [TBL] [Abstract][Full Text] [Related]
32. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Haddad AJ; Hachem RY; Moussa M; Jiang Y; Dagher HR; Chaftari P; Chaftari AM; Raad II Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473412 [TBL] [Abstract][Full Text] [Related]
33. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system. Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY medRxiv; 2023 Jan; ():. PubMed ID: 36238720 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565 [TBL] [Abstract][Full Text] [Related]
36. Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge. Yan J; Cai H; Wang J; Zhu M; Li P; Li P; Wu B; Che X; Gu L; Mou S Front Pharmacol; 2023; 14():1147980. PubMed ID: 37033654 [No Abstract] [Full Text] [Related]
37. Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study. Lopez D; Pritchard D; Sanfilippo FM; Kelty E; Page A; Etherton-Beer C; Almeida OP; Preen DB Infect Dis Now; 2024 Sep; 54(6):104953. PubMed ID: 38964717 [TBL] [Abstract][Full Text] [Related]
38. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study. Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. Lai FTT; Wang B; Wei C; Chui CSL; Li X; Cheung CL; Wong ICK; Chan EWY; Wan EYF Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141078 [TBL] [Abstract][Full Text] [Related]
40. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]